Minovia Therapeutics
Mitochondrial Augmentation Cell-therapy Platform
Company Overview
Snapshot
Founded in December 2011 by Natalie Yivgi-Ohana, Minovia Therapeutics operates with 11–50 employees. The company has raised a total of $28.35 million across 5 funding rounds from 3 investors. In June 2025, Minovia Therapeutics became publicly listed on NASDAQ.
Business overview
Minovia Therapeutics is a Health Tech & Life Sciences company focused on treating mitochondrial diseases through its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The company's core technology involves a cell therapy approach designed to address a broad range of indications stemming from mitochondrial dysfunction, including rare mitochondrial diseases and age-related conditions. Minovia serves the pharmaceutical and healthcare industries, with an initial clinical focus on rare mitochondrial diseases for which no approved treatments currently exist.
Strategic signal
In February 2026, news emerged that Launch One Acquisition Corp. would not proceed with its proposed business combination with Minovia Therapeutics. This development indicates a significant change in Minovia's planned path to public markets, suggesting a re-evaluation of its strategic options for growth and capital access. Investors should monitor how Minovia plans to navigate this change and secure future funding or market access.
Log in to access full profile ›Company Intelligence Q&A
- What is Minovia Therapeutics' primary focus?
- Minovia Therapeutics focuses on treating mitochondrial diseases using its proprietary Mitochondrial Augmentation Therapy (MAT) platform, which is a cell therapy approach.
- When did Minovia Therapeutics become a public company?
- Minovia Therapeutics became public on NASDAQ in June 2025 through a proposed business combination with Launch One Acquisition Corp.
- What significant corporate development occurred in February 2026?
- In February 2026, Launch One Acquisition Corp. announced that it would not merge with Minovia Therapeutics, indicating the termination of their proposed business combination.
- Has Minovia Therapeutics received any regulatory clearances recently?
- In April 2025, Minovia Therapeutics announced FDA clearance of its second IND application for a.
- What was a key strategic collaboration for Minovia Therapeutics in 2021?
- In July 2021, Astellas and Minovia Therapeutics announced a strategic collaboration focused on novel mitochondrial cell therapy programs.